These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14529657)

  • 1. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
    Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
    Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
    Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
    Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
    Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary.
    Klein WM; Kurman RJ
    Int J Gynecol Pathol; 2003 Apr; 22(2):181-4. PubMed ID: 12649674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
    Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
    Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT.
    Raspollini MR; Pinzani P; Simi L; Amunni G; Villanucci A; Paglierani M; Taddei GL
    Gynecol Oncol; 2005 Aug; 98(2):334-5. PubMed ID: 16039311
    [No Abstract]   [Full Text] [Related]  

  • 7. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
    Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
    Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature.
    Zafrakas M; Theodoridis TD; Zepiridis L; Venizelos ID; Agorastos T; Bontis J
    Eur J Gynaecol Oncol; 2008; 29(3):264-6. PubMed ID: 18592792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
    Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
    J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
    Mikami Y; Hata S; Kiyokawa T; Manabe T
    Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB-2 gene overexpression and amplification in uterine sarcomas.
    Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
    Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine sarcomas: a review.
    D'Angelo E; Prat J
    Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region.
    Nakayama M; Mitsuhashi T; Shimizu Y; Ban S; Ogawa F; Ishihara O; Shimizu M
    Int J Gynecol Pathol; 2006 Jan; 25(1):70-6. PubMed ID: 16306788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors.
    Kinoshita K; Isozaki K; Hirota S; Nishida T; Chen H; Nakahara M; Nagasawa Y; Ohashi A; Shinomura Y; Kitamura Y; Matsuzawa Y
    J Gastroenterol Hepatol; 2003 Feb; 18(2):147-51. PubMed ID: 12542597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
    Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
    Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
    Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
    Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ; Lee MH; Park TI; Bae HI
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
    Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
    J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
    Jeffers MD; Richmond JA; Macaulay EM
    Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target.
    Komdeur R; Hoekstra HJ; Molenaar WM; Van Den Berg E; Zwart N; Pras E; Plaza-Menacho I; Hofstra RM; Van Der Graaf WT
    Clin Cancer Res; 2003 Aug; 9(8):2926-32. PubMed ID: 12912938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.